Skip to main content

Table 4 Associations of HDAC-4 and −6 expression with clinicopathological parameters in 70 pancreatic adenocarcinoma patients

From: Histone deacetylase (HDAC)-1, −2, −4 and −6 expression in human pancreatic adenocarcinoma: associations with clinicopathological parameters, tumor proliferative capacity and patients’ survival

Clinicopathological characteristics HDAC-4 expression HDAC-6 expression
Low (%) High (%) p-value Low (%) High (%) p-value
N = 70 36 (51.4) 34 (48.6)   39 (55.7) 31 (44.3)  
Age (mean ± SD;ys)    0.9668    0.2920
  ≤66.77 ± 8.94 yrs 15 (21.4) 14 (20.0)   14 (20.0) 15 (21.4)  
  >66.77 ± 8.94 yrs 21 (30.0) 20 (28.6)   25 (35.7) 16 (22.9)  
Gender    0.7557    0.2157
  Male 22 (31.4) 22 (31.4)   27 (38.6) 17 (24.3)  
  Female 14 (20.0) 12 (17.1)   12 (17.1) 14 (20.0)  
Histopathological grade    0.4347    0.7682
  I + II 32 (45.7) 28 (40)   33 (47.1) 27 (38.6)  
  III 4 (5.7) 6 (8.6)   6 (8.6) 4 (5.7)  
pT    0.4573    0.0864
  T1 + T2 5 (7.1) 7 (10.0)   4 (5.7) 8 (11.4)  
  T3 + T4 31 (44.3) 27 (38.6)   35 (50.0) 23 (32.9)  
pN    0.0571    0.1026
  0 13 (18.6) 20 (28.6)   15 (21.4) 18 (25.7)  
  1 23 (32.9) 14 (20.0)   24 (34.3) 13 (18.6)  
pM    0.0453    0.0663
  0 32 (45.7) 34 (48.6)   35 (50.0) 31 (44.3)  
  1 4 (5.7) 0 (0.0)   4 (5.7) 0 (0.0)  
pStage    0.2818    0.0115
  I + II 27 (38.6) 29 (41.4)   27 (38.6) 29 (41.4)  
  III + IV 9 (12.9) 5 (7.1)   12 (17.1) 2 (2.9)  
Ki-protein statement    0.0576    0.5379
  ≤ median value 24 (34.3) 15 (21.4)   23 (32.9) 16 (22.9)  
  > median value 12 (17.1) 19 (27.1)   16 (22.9) 15 (21.4)